Skip to content

SW · MED.SW · MEDICAL - DEVICES

Medartis Holding AG (MED.SW) intrinsic value and stock valuation

$114.20as of 2026-11-21 · Mkt cap 958.58M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medartis Holding AG DCF and intrinsic value

InvestorsCraft values MED.SW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MED.SW’s statements →

Medartis Holding AG Graham Number

Graham Number: $18.29d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Basel 4057 medartis.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$269.3M+16.1% 5y CAGRd
20152025
Net income
$8.35M
20152025
Free cash flow
$9.34M
20152025
Total equity
$275.9M+5.3% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$269.3M$224.8M$212M$182.8M$159.9M
Operating income$1.93M$7.87M$9.1M-$-1.92M$11M
Net income$8.35M$3.53M$620K-$-5.78M$6.84M
EPSd$670.7K$284.4K$50.7K-$-488.59K$579.7K
Operating cash flow$34.8M$28.2M$20M-$-3.93M$21M
Capital expenditure-$-25.48M-$-7.17M-$-14.93M-$-18.79M-$-10.39M
Free cash flow$9.34M$21M$5.05M-$-22.72M$10.6M
Total assets$559.9M$460M$349.5M$327.9M$298.2M
Total debt$157.7M$121.2M$27.4M$28M$24.1M
Net debt$124.8M-$-18.39M$2.19M$7.35M-$-58.57M
Total equity$275.9M$269.7M$255M$237.8M$224M
Cash and short-term investments$33M$138.7M$25.2M$20.6M$82.6M
Income statement
20252024202320222021
Revenue$269.3M$224.8M$212M$182.8M$159.9M
Cost of revenue$64.9M$46.2M$44.4M$47.4M$38.3M
Gross profit$204.3M$178.7M$167.6M$135.4M$121.6M
Research and development expenses$31.4M$43.1M$25.9M$23.5M$20.1M
Selling, general and administrative expenses$172.7M$140.5M$132M$126M$103.1M
Other expenses-$-1.76M-$-12.79M$570K$1.87M-$-40K
Operating expenses$202.4M$170.8M$158.5M$151.4M$123.1M
Cost and expenses$267.3M$217M$202.9M$184.7M$148.9M
Interest income$1.31M$1.33M$340K$250K$140K
Interest expense$7.48M$6.8M$1.73M$4.62M$1.47M
Depreciation and amortization$25.5M$22.3M$13.3M$18.1M$16.4M
Ebitda$45.7M$30.2M$24.7M$15.6M$26.1M
Operating income$1.93M$7.87M$9.1M-$-1.92M$11M
Total other income/expenses, net$10.9M-$-6M-$-7.31M-$-5.22M-$-2.77M
Income before tax$12.8M$1.86M$1.79M-$-7.14M$8.29M
Income tax expense$3.45M-$-1.03M$1.17M-$-1.36M$1.45M
Net income$8.35M$3.53M$620K-$-5.78M$6.84M
Weighted average shares outstanding$12.4M$12.4M$12.2M$11.8M$11.8M
Weighted average diluted shares outstanding$12.5M$12.4M$12.2M$11.8M$11.8M
Balance sheet
20252024202320222021
Cash and short-term investments$33M$138.7M$25.2M$20.6M$82.6M
Net receivables$60.9M$46.2M$46.4M$45M$36.4M
Inventory$98.2M$79.2M$68.3M$69.9M$54.3M
Total current assets$195.3M$265.9M$141.4M$137.9M$175.5M
Property, plant and equipment, net$94.1M$76M$80.1M$79.3M$64.6M
Goodwill and intangible assets$241.4M$51.9M$64.7M$108.5M$14.5M
Long-term investments$1.28M$35.2M$34.3M$15.4M$16.6M
Total non-current assets$364.6M$194M$208.1M$190M$122.7M
Total assets$559.9M$460M$349.5M$327.9M$298.2M
Accounts payable$16.1M$8.86M$8.24M$9.6M$8.24M
Short-term debt$26.2M$7.78M$6.76M$5.62M$9.17M
Deferred revenue$0.00$0.00$680K$680K$640K
Total current liabilities$88.2M$51M$46M$39.5M$34.7M
Long-term debt$131.5M$113.4M$20.6M$22.3M$19.5M
Deferred revenue, non-current$0.00$480K$0.00$0.00$0.00
Total non-current liabilities$195.9M$139.3M$48.6M$50.6M$39.5M
Capital lease obligations$27.5M$25.2M$26.9M$27M$24.1M
Total liabilities$284.1M$190.3M$94.6M$90.1M$74.2M
Common stock$2.73M$2.72M$2.47M$2.37M$2.36M
Retained earnings-$-8.18M-$-19.3M-$-30.84M-$-23.05M-$-34.13M
Accumulated other comprehensive income (loss)$281.6M$286.5M$283.3M$258.5M$255.8M
Total equity$275.9M$269.7M$255M$237.8M$224M
Total investments$1.28M$35.2M$34.3M$15.4M$16.6M
Total debt$157.7M$121.2M$27.4M$28M$24.1M
Net debt$124.8M-$-18.39M$2.19M$7.35M-$-58.57M
Cash flow statement
20252024202320222021
Net income$9.34M$3.53M$620K-$-5.78M$6.84M
Depreciation and amortization$25.5M$22.3M$21M$18.1M$16.4M
Stock-based compensation$1.56M$0.00$1.53M$2.2M$2.3M
Change in working capital$9.59M-$-7.36M$2.62M-$-19.28M-$-5.76M
Accounts receivable-$-2.47M$40K-$-270K-$-7.46M-$-10.05M
Inventory$5.72M-$-10.85M$1.6M-$-9.04M-$-4.75M
Accounts payable$0.00$3.45M$1.28M-$-2.78M$9.04M
Net cash provided by operating activities$34.8M$32.1M$20M-$-3.93M$21M
Investments in property, plant and equipment-$-18.67M-$-11.09M-$-14.93M-$-18.79M-$-10.39M
Acquisitions, net-$-108.85M$340K$30K-$-35.86M$70K
Net cash used for investing activities-$-146.26M-$-19.06M-$-37.83M-$-52.91M-$-15.87M
Common stock issued$710K$630K$29.8M$1.88M$680K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.83M$100.6M$23.2M-$-3.9M-$-4.78M
Net change in cash-$-105.72M$113.5M$4.6M-$-62.04M-$-90K
Cash at end of period$33M$138.7M$25.2M$20.6M$82.6M
Operating cash flow$34.8M$28.2M$20M-$-3.93M$21M
Capital expenditure-$-25.48M-$-7.17M-$-14.93M-$-18.79M-$-10.39M
Free cash flow$9.34M$21M$5.05M-$-22.72M$10.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medartis Holding AG

        Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. The company offers osteosynthesis instruments for the areas of the hand, wrist, elbow, shoulder, and foot and ankle, as well as for the areas of the mandible, midface, orthognathic, and cranium under the APTUS and MODUS names. The company serves the surgeons, hospitals, and medical centers, as well as group purchasing organizations. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.

        CEO
        Matthias Schupp
        Employees
        816
        Beta
        1.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Medartis Holding AG (MED.SW)?

        InvestorsCraft does not currently publish an intrinsic value for MED.SW. How the IC value is calculated.

        Is MED.SW undervalued?

        InvestorsCraft does not publish an undervaluation signal for MED.SW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.